These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26845207)

  • 21. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
    Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically important drug interactions with disease-modifying antirheumatic drugs.
    Haagsma CJ
    Drugs Aging; 1998 Oct; 13(4):281-9. PubMed ID: 9805209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic of antirheumatic treatments: clinical implications.
    Ferraccioli G; Tolusso B; De Santis M
    Pharmacogenomics J; 2007 Feb; 7(1):2-9. PubMed ID: 16702980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on methotrexate.
    Braun J; Rau R
    Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
    Suzuki Y; Wakabayashi T; Saito E; Suwa A
    Clin Calcium; 2007 Apr; 17(4):546-52. PubMed ID: 17404484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Trends in the treatment of rheumatic diseases].
    Trotta F; Padovan M
    Recenti Prog Med; 1999 Oct; 90(10):510-4. PubMed ID: 10592735
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
    Betancourt BY; Biehl A; Katz JD; Subedi A
    Rheum Dis Clin North Am; 2018 Aug; 44(3):371-391. PubMed ID: 30001781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2009 Mar; 19(3):395-403. PubMed ID: 19252250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 37. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New age of biological therapies in paediatric rheumatology.
    Sen ES; Ramanan AV
    Arch Dis Child; 2014 Jul; 99(7):679-85. PubMed ID: 24621445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethnic differences in responses to disease modifying drugs.
    Helliwell PS; Ibrahim G
    Rheumatology (Oxford); 2003 Oct; 42(10):1197-201. PubMed ID: 12810940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.